- Home
- ORMP vs ATOS Comparison
ORMP vs ATOS Comparison
Compare ORMP & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORMP
- ATOS
- Stock Information
- Founded
- ORMP 2002
- ATOS 2009
- Country
- ORMP United States
- ATOS United States
- Employees
- ORMP N/A
- ATOS N/A
- Industry
- ORMP Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- ORMP Health Care
- ATOS Health Care
- Exchange
- ORMP Nasdaq
- ATOS Nasdaq
- Market Cap
- ORMP 104.6M
- ATOS 106.9M
- IPO Year
- ORMP N/A
- ATOS 2012
- Fundamental
- Price
- ORMP $2.21
- ATOS $0.81
- Analyst Decision
- ORMP
- ATOS Strong Buy
- Analyst Count
- ORMP 0
- ATOS 3
- Target Price
- ORMP N/A
- ATOS $6.25
- AVG Volume (30 Days)
- ORMP 135.0K
- ATOS 768.2K
- Earning Date
- ORMP 11-07-2025
- ATOS 11-12-2025
- Dividend Yield
- ORMP N/A
- ATOS N/A
- EPS Growth
- ORMP N/A
- ATOS N/A
- EPS
- ORMP N/A
- ATOS N/A
- Revenue
- ORMP $2,000,000.00
- ATOS N/A
- Revenue This Year
- ORMP N/A
- ATOS N/A
- Revenue Next Year
- ORMP N/A
- ATOS N/A
- P/E Ratio
- ORMP N/A
- ATOS N/A
- Revenue Growth
- ORMP N/A
- ATOS N/A
- 52 Week Low
- ORMP $1.82
- ATOS $0.55
- 52 Week High
- ORMP $3.09
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- ORMP 38.97
- ATOS 33.96
- Support Level
- ORMP $2.30
- ATOS $0.86
- Resistance Level
- ORMP $2.40
- ATOS $0.91
- Average True Range (ATR)
- ORMP 0.11
- ATOS 0.04
- MACD
- ORMP -0.02
- ATOS -0.02
- Stochastic Oscillator
- ORMP 33.33
- ATOS 12.21
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.